AlphaYou
Overview
Smart money at a glance
Filings to Oct 6, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- 52-wk high
- $35.64
- 52-wk low
- $1.37
- Mkt cap
- $3.2M
- P/E
- 0.0x
- Fwd P/E
- 3.9x
- Beta
- 1.61
- P/S
- 2.7x
- P/B
- 0.6x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -420.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about APVO filings
Are insiders buying or selling Aptevo Therapeutics Inc (APVO) stock?
Neither. Aptevo Therapeutics Inc (APVO) insiders filed no open-market purchases or sales in the 90 days to Oct 6, 2026, according to SEC Form 4 filings.
Which members of Congress have traded APVO recently?
None. No member of Congress disclosed a APVO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this APVO smart-money data?
This summary uses filings available on Oct 6, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
How top traders are positioned
No tracked top-trader positions in APVO right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 11.8% above what analysts expected.
Last report
Aug 10, 2026
Period ending
Jun 30, 2026
Earnings per share
-$6.02 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | -$5.31 / -$6.02Alpha Vantage | +11.79% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 13, 2026 | -$6.41 / -$5.60Alpha Vantage | -14.46% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 20, 2026 | -$5.91 / -$8.09Alpha Vantage | +26.94% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$40.14 / -$37.62Alpha Vantage | -6.70% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 11, 2025 | -$151.20 / -$1497.60Alpha Vantage | +89.90% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 15, 2025 | -$4.39 / -$4.21Alpha Vantage | -4.28% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 4, 2025 | -$3218.40 / -$2790.00Alpha Vantage | -15.35% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$6393.60 / -$7592.40Alpha Vantage | +15.79% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 30 days
Financials
Is the business strong?
Fairly priced and running thin margins.
- Net margin
- 0.0%
- P/E
- 0.00
- Forward P/E
- 3.89
- Market cap
- $3M
Valuation
- P/S2.70
- P/B0.57
Quality
- Operating margin0.0%
- ROE-420.3%
- ROA-111.5%
Growth
- Beta1.61
Technicals
Price structure
Market data unavailable.